gasguide

Tranexamic Acid (TXA) — Detail

Cyklokapron · Lysteda (PO)

Antifibrinolytic / synthetic lysine analog

Synthetic lysine analog. Competitively binds plasminogen LYSINE binding sites, preventing plasminogen activation to plasmin. Inhibits fibrinolysis without inducing hypercoagulability per se.

Indications

  • Trauma hemorrhage (CRASH-2: 1g IV over 10 min + 1g over 8 h within first 3 h reduces all-cause mortality)
  • Postpartum hemorrhage (WOMAN trial: 1g IV reduces death from bleeding)
  • Cardiac surgery (reduces blood loss + transfusion)
  • Spine surgery, total joint, liver transplant
  • Hereditary angioedema prophylaxis
  • Heavy menstrual bleeding (PO formulation)

Dosing

ContextAdultPediatric
Trauma (CRASH-2)1 g IV over 10 min within FIRST 3 H of injury, then 1 g over 8 h
Postpartum hemorrhage (WOMAN)1 g IV over 10 min as soon as PPH diagnosed; can repeat 30 min later
Cardiac surgeryLoading 10-30 mg/kg IV + infusion 1-16 mg/kg/h
Spine/major ortho10-15 mg/kg IV at incision; some institutions add infusion
Topical (joint, surgical field)1-3 g in 100-200 mL saline applied topically
Pediatric (e.g. congenital cardiac)(weight-based)10 mg/kg IV at induction + 1 mg/kg/h infusion

Pharmacokinetics

Onset 5-10 min IV. Half-life ~2-3 h. Renal excretion >95% unchanged.

Hemodynamic effects

Hemodynamically neutral. Rapid IV bolus may cause transient hypotension or visual disturbances — give over 10 min for 1 g dose.

Side effects

  • !Visual disturbances + hypotension (rapid bolus) — give over ≥10 min
  • !Seizures (high-dose cardiac surgery — TXA is GABAA antagonist; reduce dose with CSF leak / BBB disruption)
  • !Theoretical thromboembolism increase — meta-analyses show no clear increase
  • !GI upset (PO)
  • !Headache + nausea

Contraindications

  • ×Active intravascular thrombosis (PE, DVT being treated)
  • ×Subarachnoid hemorrhage (some debate)
  • ×Severe renal impairment (dose reduction)
  • ×Acute color vision deficit

Clinical pearls

  • TIMING for trauma: 1 g WITHIN 3 HOURS reduces mortality. After 3 hours, NOT beneficial and may HARM.
  • PPH: 1 g IV as soon as diagnosed; can repeat 30 min later.
  • CARDIAC SURGERY: reduces bleeding + transfusion ~25%. Seizure risk at high-dose protocols (>50 mg/kg) — modern dose more conservative (10-30 mg/kg).
  • SPINE SURGERY: 15 mg/kg IV at incision is standard — reduces blood loss + transfusion in scoliosis + multilevel fusion.
  • TOPICAL: 1-3 g in saline applied to surgical wound (knee, hip) reduces bleeding without systemic exposure.
  • Approximately $5-10 per dose IV — extreme cost-effectiveness.
Education only — confirm against current package inserts and institutional protocols. Doses assume normal organ function unless otherwise noted.